Steve Reed Steps Down as CEO of IDRI to Lead Two Spinout Companies

Steve Reed, president and CEO of the Infectious Disease Research Institute (IDRI), is stepping down from his executive roles. Seattle-based IDRI says Reed will lead two spinouts: OnCo, which will focus on cancer immunotherapies for the developed world, and HDT Bio, which is developing immunotherapies and vaccines. Reed will also continue as a distinguished investigator at IDRI, the nonprofit research organization he founded in 1993. Corey Gasper, IDRI’s chief scientific and medical officer, has been appointed interim president and CEO.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan